bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for 510(k) clearance of the BIOFIRE® Blood Culture Identification 2 (BCID2) Panel. The BIOFIRE® BCID2 Panel includes several additional pathogens, an expanded list of antimicrobial resistance genes, and many revised targets compared to the existing BIOFIRE® BCID Panel.
bioMérieux, a world leader in the field of in vitro diagnostics, today released its quarterly business review for the six months ended June 30, 2016.
bioMerieux Receives FDA Clearance for Expanded Use of VIDAS® B•R•A•H•M•S PCT™ Test for Managing Sepsis Patients with Elevated Risk of Mortality
Tracking PCT – a biomarker for bacterial infections – over time provides strong indication of likely mortality, enabling physicians to personalize care for high-risk patients.
bioMérieux and the Lyon Civil Hospitals strengthen their collaboration and expand their partnership to include Claude Bernard University Lyon 1 Two joint research laboratories focused on a common goal: advancing medical research for the benefit of patients.
bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the three months ended March 31, 2016.